SCHOTT Pharma shares climbed sharply on Thursday after the company issued preliminary figures for the third quarter of fiscal 2026 following Wednesday's market close. The injectable drug packaging specialist reported constant-currency revenue growth of approximately 8% and an EBITDA margin of about 27%, results that outpaced prevailing market expectations.
Management responded to the stronger-than-expected quarter by raising its full-year fiscal 2026 guidance. The company now expects constant-currency revenue growth of 5-6%, up from a prior range of 2-5%. The EBITDA margin target was also nudged higher to 27-28% from approximately 27%. Both upgrades exceeded current analyst expectations and provided a fresh positive data point for investors.
In a separate disclosure, SCHOTT Pharma said it reached a settlement with a key glass syringe customer. That dispute had been the cause of a profit warning published in December 2025 and had weighed on investor sentiment since. Management indicated the settlement resolves that outstanding issue, removing a notable overhang on the injectable drug packaging business.
Broker sentiment turned more constructive in response to the company’s announcements. RBC Capital upgraded SCHOTT Pharma from Sector Perform to Outperform and raised its price target from 18 to 21, with analyst Charles Weston noting that the preliminary Q3 results addressed remaining concerns about the injectable packaging business. This upgrade followed Deutsche Bank's July 6 decision to lift its rating to Buy with a 22 price target, pointing to a broader shift in analyst views that had been forming ahead of the latest results.
The macro setting provided a supportive backdrop. The DAX recovered 0.5% to 25,023 points and the MDax rose 0.9% to 31,806 points on Thursday, as equities rebounded after a two-day selloff attributed to shifts in AI sentiment and tensions in the Middle East. Observers noted that the sector recovery among German mid-caps helped underpin risk appetite, although SCHOTT Pharma's share move was driven mainly by company-specific developments rather than the index tailwind.
On the trading day in question, the stock moved from a prior close of 17.62 to an intraday high of 21.50, representing its most pronounced single-session gain in recent memory. At the time of reporting, shares were trading around 20.30, up 15.2% for the session, and standing well above their 52-week low of 12.62.
Contextual note - The price reaction encompassed several layered catalysts: a material Q3 outperformance, an upgraded full-year outlook, resolution of a customer dispute that had previously prompted a profit warning, and consecutive analyst upgrades. Together these factors created a concentrated positive impulse for the stock.